Seagen hasn't let a pending acquisition by Pfizer interrupt its business development activities, adding to its pipeline with a wide-ranging partnership with Nurix Therapeu
Gilead Sciences clearly liked what it saw in the early stages of its 2019 partnership with Nurix on protein degradation drugs – it has just opted into the first of five po
In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho